ArticleFrontiers in oncology2025

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

J-P Machiels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.